|
|
|
|
Antiphospholipid Antibody-Associated Chorea More Common in Women
NEW YORK (Reuters Health) Dec 10 - Antiphospholipid antibody (aPL)-associated chorea is of mild to moderate severity and is found most often in women, according to research conducted at the Mayo Clinic, Rochester, Minnesota.However,...
|
|
|
Antiphospholipid Antibody-Associated Chorea More Common in Women
_ Antiphospholipid Antibody-Associated Chorea More Common in Women.
|
|
|
Arsenic: medicinal double-edged sword
Despite its proven therapeutic benefits, concerns of toxicity and carcinogenicity caused a decline in the medicinal use of arsenic.Print Email Discuss in our forum For more than 2,400 years, arsenic from the Greek word arsenikon meaning...
|
|
|
Researchers at College of Medicine, Division of Rheumatology have published new data on chorea therapy
- (NewsRx.com) -- A new study, 'Antiphospholipid antibody-associated chorea,' is now available (see also Chorea Therapy).'To describe the clinical features, treatment, and outcomes of patients with antiphospholipid antibody ...
|
|
|
After state's Proposal 2, U. Mich. prepares to expand stem cell research
After state's Proposal 2, U.Mich. prepares to expand stem cell researchBy Elaine LaFayDecember 02, 2008 Source: Michigan Daily, U. Michigan After waiting years for changes to the states restrictive stem cell research laws, University...
|
|
|
Cambridge Laboratories Announces Launch of XENAZINE(R) (Tetrabenazine) in the US
First Approved Treatment for Chorea Associated With Huntington's Disease NEWCASTLE, England, December 1 (HSMN NewsFeed) -- Cambridge Laboratories Group Limited ('Cambridge'), the privately-owned specialty pharmaceutical company, today...
|
|
|
Cambridge Laboratories announces launch of Huntington's drug in US
Cambridge Laboratories Group, a specialty pharmaceutical company, has announced the launch of Xenazine, the first and only product said to be approved for the treatment of chorea associated with Huntington's disease in the US.The...
|
|
|
Cambridge Laboratories Announces Launch of XENAZINE(R) (Tetrabenazine) in the US
NEWCASTLE, England, December 1 /PRNewswire/ -- Cambridge Laboratories Group Limited ('Cambridge'), the privately-owned specialty pharmaceutical company, today announces that XENAZINE (tetrabenazine), the first and only product approved for...
|
|
|
Boost for Biovail and Cambridge Labs as Xenazine gets US launch
Biovail and marketing partner Cambridge Laboratories Group are celebrating the launch in the USA of Xenazine, the first product approved for the treatment of chorea associated with Huntington's disease.The US Food and Drug...
|
|
|
Cambridge Laboratories announces launch of Huntington's drug in US
(Datamonitor via COMTEX) -- PWCK | Quote | Chart | News | PowerRating -- Cambridge Laboratories Group, a specialty pharmaceutical company, has announced the launch of Xenazine, the first and only product said to be approved for the treatment...
|
|
|
Cambridge Laboratories Announces Launch Of XENAZINE(R) (Tetrabenazine) In The US
('Cambridge'), the privately-owned specialty pharmaceutical company, today announces that XENAZINE(R) (tetrabenazine), the first and only product approved for the treatment of chorea associated with Huntington's disease, has been...
|
|
|
Cambridge Laboratories Announces Launch of XENAZINE(R) (Tetrabenazine) in the US
NEWCASTLE, England, December 1 /PRNewswire/ -- Cambridge Laboratories Group Limited ('Cambridge'), the privately-owned specialty pharmaceutical company, today announces that XENAZINE (tetrabenazine), the first and only product approved for...
|
|
|
Biovail Announces U.S. Availability of Xenazine Tablets
We are delighted to be involved in bringing this important product to market, said Biovail Chief Executive Officer Bill Wells.Xenazine is the first commercial product stemming from our New Strategic Focus one that targets unmet medical...
|
|
|
The First Treatment Specifically Approved for Huntington's Disease Patients is Now Available in the United Sta
/PRNewswire/ -- Xenazine(R) (tetrabenazine) Tablets, the first and only U.S.Food and Drug Administration (FDA) approved drug for the treatment of chorea associated with Huntington's Disease (HD), is now available in the United...
|
|
|
Biovail Reports Third-Quarter 2008 Financial Results
- Biovail Corporation (NYSE/TSX: BVF) today announced financial results for the three-month and nine-month periods ended September 30, 2008.To the extent that this news release contains forward-looking statements, investors are cautioned...
|
|
|
Getting at the Root of Vertical Diplopia
Over a series of articles, Im reviewing the causes, diagnosis and treatment options for patients with vertical diplopia.The initial discussion focused on contribution of the orbital muscles and clinical tests to assess this component of...
|
|
|
Proteins within the type E botulinum neurotoxin complex
Title: United States Patent: 7,431,935 Inventors: Singh; Bal Ram (Dartmouth, MA), Zhang; Zhong (New Bedford, MA) Assignee: University of Massachusetts (Boston, MA) Appl.No.: 10/766,283 Filed: January 27, 2004 The invention features a...
|
